Cancer clinical trials in the region Île-de-France

703 currently recruiting clinical trials
Region Île-de-France

Phase 3 Lung cancer #NCT05899608 #2024-513087-26-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Summit Therapeutics
Phase 3 Lung cancer #NCT07361510 #2025-523586-18-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Bristol-Myers Squibb
Phase 3 Skin cancer #NCT06112314
Required histologic types
Melanoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Immunocore Ltée
Phase 3 Skin cancer #NCT05549297
Required histologic types
Melanoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Immunocore Ltée
Phase 3 Skin cancer #NCT05727904 #2022-503140-41-00
Required histologic types
Melanoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Iovance Biotherapeutics
Phase 3 Colon cancer Rectal cancer Anal cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Small intestine and appendix cancer #NCT07087054 #2024-519875-24-00
Required histologic types
Ileum cancer
Required histologic sub types
Neuroendocrine tumor
Required number of previous lines of therapy for current stage of disease
None
6 recruiting sites
Crinetics Pharmaceuticals Inc.
Phase 3 Breast cancer #NCT06103864 #2023-503675-24-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
AstraZeneca
Phase 3 Breast cancer #NCT06103864 #2023-503675-24-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%)
8 recruiting sites
AstraZeneca
Phase 3 Colon cancer Rectal cancer #NCT07228832 #2025-521587-35-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRAF MSI/dMMR
Excluded previous treatments at localized stage
Immunotherapy Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Targeted therapy
8 recruiting sites
Summit Therapeutics
Phase 3 Pancreas cancer #NCT07252232 #2025-523495-23-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
Other KRAS HRAS KRAS G12C KRAS G12D KRAS non G12C NRAS RAS
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy
Excluded previous treatments at localized stage
Targeted therapy
3 recruiting sites
Revolution Medicines, Inc.